Survodutide

Independent test grades (7 vendors)

Aggregated from Finnrick (independent testing). Their grades, attributed — not our verdict.

Research literature (8)

Consolidated from PubMed — each links to the original record.

• Emerging pharmacotherapies for obesity: A systematic review.

  Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L · Pharmacological reviews · 2025 · PMID 39952695

• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

  Singh A, Sohal A, Batta A · World journal of gastroenterology · 2024 · PMID 39735270

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

  Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E · The New England journal of medicine · 2024 · PMID 38847460

• Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

  Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N · Journal of hepatology · 2024 · PMID 38857788

• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

  le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM · The lancet. Diabetes & endocrinology · 2024 · PMID 38330987

• Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

  Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM · Diabetologia · 2024 · PMID 38095657

• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

  Drucker DJ · Diabetes care · 2024 · PMID 38843460

• Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.

  Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S · JACC. Heart failure · 2024 · PMID 39453356

FAQ

What is Survodutide?

Survodutide (2805997-46-8, BI-456906, GLXC-27923) is classified under glp-1 & incretin agonists. Research goals associated with it include metabolic & weight.

Is Survodutide FDA-approved?

The regulatory status of Survodutide is not established in our sources.

What does the research on Survodutide say?

peptideone aggregates 8 references from PubMed for Survodutide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.